Seizure News and Research RSS Feed - Seizure News and Research

An epileptic seizure, occasionally referred to as a fit, is defined as a transient symptom of "abnormal excessive or synchronous neuronal activity in the brain".

Researchers discover that anti-seizure drug reduces alcohol consumption

Boston-Researchers from Boston University School of Medicine (BUSM) have discovered that the anti-seizure drug ezogabine, reduced alcohol consumption in an experimental model. The findings, reported in the American Journal of Drug and Alcohol Abuse, may lead to more effective treatments for alcoholism. [More]
Young people with epilepsy are more than twice as likely to be poisoned by medication

Young people with epilepsy are more than twice as likely to be poisoned by medication

Children and young adults with epilepsy are more likely to suffer broken bones, burns and poisonings compared to those without the neurological disorder, new research has found. [More]

Experts create new definition for epilepsy

An expert task force has created a new definition for epilepsy that refines the scope of patients diagnosed with this brain disease. The study published in Epilepsia, a journal published by Wiley on behalf of the International League Against Epilepsy, provides a greater level of detail to diagnose epilepsy by including individuals with two unprovoked seizures, and those with one unprovoked seizure and other factors that increase risk of seizure recurrence. [More]
Astellas, Medivation submit European Marketing Authorization Application for XTANDI capsules

Astellas, Medivation submit European Marketing Authorization Application for XTANDI capsules

Astellas Pharma Inc. and Medivation Inc. today announced the submission of a variation to amend the European Marketing Authorization Application for XTANDI® (enzalutamide) capsules for the treatment of adult men with metastatic castration-resistant prostate cancer (mCRPC) who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy and in whom chemotherapy is not yet clinically indicated. [More]

rEVO Biologics commences ATryn Phase 3 clinical program for treatment of preeclampsia in pregnant women

rEVO Biologics Inc., a subsidiary of LFB SA, today announced the initiation of the Phase 3 clinical program for ATryn for the treatment of preeclampsia in pregnant women during the 24th to 28th week of pregnancy. [More]
Study links effect of gastric bypass surgery on glucose metabolism and islet function in hypoglycemia patients

Study links effect of gastric bypass surgery on glucose metabolism and islet function in hypoglycemia patients

University of Cincinnati (UC) researchers have discovered that altered islet cell function and reduced insulin clearance contribute to excessive post-meal insulin response in patients experiencing low blood sugar symptoms (hypoglycemia) following gastric bypass surgery. [More]
SAGE Therapeutics doses first patient in SAGE-547 Phase 1/2 trial for treatment of SRSE

SAGE Therapeutics doses first patient in SAGE-547 Phase 1/2 trial for treatment of SRSE

SAGE Therapeutics, a biopharmaceutical company developing novel medicines to treat life-threatening and rare central nervous system (CNS) disorders, today announced dose initiation of the first patient in a Phase 1/2 clinical trial of SAGE-547, a neuroactive steroid, in super-refractory status epilepticus (SRSE), a critical condition in which the brain is in a state of persistent seizure. [More]
Study: Mood stabilizing drug may help prevent head and neck cancer

Study: Mood stabilizing drug may help prevent head and neck cancer

A new study indicates that a commonly used mood stabilizing drug may help prevent head and neck cancer. The study is published early online in Cancer, a peer-reviewed journal of the American Cancer Society. [More]
Sea lions exposed to toxin in algae develop form of epilepsy that is similar to humans

Sea lions exposed to toxin in algae develop form of epilepsy that is similar to humans

California sea lions exposed to a toxin in algae develop a form of epilepsy that is similar to one in humans, according to a new study led by Stanford University School of Medicine researchers. [More]

Researcher detects higher rate of seizures among children with autism who were fed soy formula

A University of Wisconsin-Madison researcher has detected a higher rate of seizures among children with autism who were fed infant formula containing soy protein rather than milk protein. [More]

SAGE Therapeutics announces completion of $38 million Series C financing

SAGE Therapeutics, a biopharmaceutical company developing novel medicines to treat specialty, critical and orphan central nervous system (CNS) disorders, today announced the successful completion of a $38 million Series C financing. OrbiMed Advisors, LLC, EcoR1 Capital Management, Foresite Capital Management and two undisclosed blue chip public investment funds joined existing investors Third Rock Ventures and ARCH Venture Partners. [More]

Three innovative tools to detect, test and initiate personalized drug treatment for seizures

A team of researchers from the National Institutes of Health, Emory University and Cedars-Sinai - specialists in identifying and treating very rare diseases - used three innovative tools to detect a previously unknown gene mutation, test potential therapies in the lab, and initiate personalized drug treatment for a boy with a lifelong history of uncontrollable seizures that caused significant impact on his cognitive and social development. [More]
FDA accepts Lundbeck's carbamazepine NDA for review

FDA accepts Lundbeck's carbamazepine NDA for review

Lundbeck LLC today announced that the U.S. Food and Drug Administration has accepted for review a New Drug Application (NDA) for its investigational therapy intravenous carbamazepine, an intravenous formulation of the anti-epileptic drug (AED) carbamazepine. An action letter is anticipated before the end of 2014. Carbella is the proposed U.S. trade name for intravenous carbamazepine. [More]
FDA approves KALYDECO for people with cystic fibrosis

FDA approves KALYDECO for people with cystic fibrosis

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) approved a supplemental New Drug Application (sNDA) for KALYDECOTM (ivacaftor) for people with cystic fibrosis (CF) ages 6 and older who have one of eight additional mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. KALYDECO was first approved in January 2012 for people with CF ages 6 and older who have at least one copy of the G551D mutation. [More]

Longer looks: Doctor training for ADHD, Obamacare and epilepsy, clues in a drop of blood

Jerry, 9 years old, dissolved into his Game Boy while his father described his attentional difficulties to the family pediatrician. [More]
New smart phone app may help people detect epileptic seizures and treat stroke

New smart phone app may help people detect epileptic seizures and treat stroke

Two new smart phone applications may help people detect epileptic seizures and get better stroke treatment, according to two studies released today that will be presented at the American Academy of Neurology's 66th Annual Meeting in Philadelphia, April 26 to May 3, 2014. [More]

Cyberonics receives CE Mark approval in Europe for AspireSR generator

Cyberonics, Inc. announced today the CE Mark (Conformité Européenne) approval in Europe for the AspireSR generator, the novel sixth-generation VNS Therapy generator. [More]

Researchers explore possible link between metabolic defects and seizures

Researchers from the Franciscan University of Steubenville, Ohio are exploring a possible link between metabolic defects and seizures. They determined that diet could influence susceptibility to seizures, and they have identified a common diabetes drug that could be useful in treating disorders such as epilepsy. [More]
Forest Laboratories plans to discontinue sale of NAMENDA 5 mg and 10 mg tablets

Forest Laboratories plans to discontinue sale of NAMENDA 5 mg and 10 mg tablets

Forest Laboratories, Inc., a leading, fully integrated, specialty pharmaceutical company largely focused on the United States market, today announced that it plans to discontinue the sale of NAMENDA (memantine HCl) 5 mg and 10 mg tablets effective August 15, 2014. [More]
Study reveals that more than 14% of pregnant women are prescribed opioids for pain

Study reveals that more than 14% of pregnant women are prescribed opioids for pain

More than 14 percent of pregnant women were prescribed opioids (narcotics) for pain at some time during their pregnancy, according to a study posted to the online version of Anesthesiology. [More]